FDA offers AstraZeneca a shortcut on a landmark SGLT2 approval while China greenlights Lokelma
The FDA may have snubbed AstraZeneca in its quest to expand the approval of its SGLT2 diabetes drug to type 1 patients, but regulators …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
